Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $14.00

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.00.

A number of brokerages have recently weighed in on ATRA. The Goldman Sachs Group dropped their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 13th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics during the second quarter worth approximately $53,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at about $79,000. Delap Wealth Advisory LLC acquired a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at about $29,000. BNP Paribas Financial Markets grew its stake in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after buying an additional 86,842 shares during the last quarter. Finally, Redmile Group LLC increased its position in Atara Biotherapeutics by 1.7% during the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after buying an additional 156,863 shares during the period. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Price Performance

NASDAQ ATRA opened at $8.83 on Thursday. The stock has a market capitalization of $42.53 million, a P/E ratio of -0.17 and a beta of 0.50. The firm’s 50-day moving average is $8.08 and its two-hundred day moving average is $10.82. Atara Biotherapeutics has a 12 month low of $4.96 and a 12 month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The company had revenue of $28.64 million for the quarter, compared to analysts’ expectations of $48.30 million. As a group, analysts anticipate that Atara Biotherapeutics will post -12.09 EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.